TNGX

Tango Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 4/10
  • Value↓ 0/10
Tango Therapeutics sales and earnings growth
TNGX Growth
Neutral
  • Revenue Y/Y↑ 48.29%
  • EPS Y/Y↑ 26.89%
  • FCF Y/Y↓ -5.81%
Tango Therapeutics gross and profit margin trends
TNGX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -162.90%
  • ROIC 5Y↓ -39.86%
Tango Therapeutics net debt vs free cash flow
TNGX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Tango Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗